155 related articles for article (PubMed ID: 21857690)
1. Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
Tagawa ST; Beltran H
Asian J Androl; 2011 Nov; 13(6):785-6. PubMed ID: 21857690
[No Abstract] [Full Text] [Related]
2. Abiraterone and its place in the treatment of metastatic CRPC.
Sartor O; Pal SK
Nat Rev Clin Oncol; 2013 Jan; 10(1):6-8. PubMed ID: 23149889
[TBL] [Abstract][Full Text] [Related]
3. [Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Heck MM; Höppner M; Horn T; Thalgott M; Gschwend JE; Retz M
Urologe A; 2012 Mar; 51(3):390-7. PubMed ID: 22331349
[TBL] [Abstract][Full Text] [Related]
4. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Danila DC; Morris MJ; de Bono JS; Ryan CJ; Denmeade SR; Smith MR; Taplin ME; Bubley GJ; Kheoh T; Haqq C; Molina A; Anand A; Koscuiszka M; Larson SM; Schwartz LH; Fleisher M; Scher HI
J Clin Oncol; 2010 Mar; 28(9):1496-501. PubMed ID: 20159814
[TBL] [Abstract][Full Text] [Related]
5. [New treatments for castration-resistant prostate cancer].
Sautois B; Gennigens C
Rev Med Liege; 2013 Feb; 68(2):94-6. PubMed ID: 23469490
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone and increased survival in metastatic prostate cancer.
de Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Fléchon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Kheoh T; Haqq CM; Scher HI;
N Engl J Med; 2011 May; 364(21):1995-2005. PubMed ID: 21612468
[TBL] [Abstract][Full Text] [Related]
8. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
Sorensen S; Ellis L; Wu Y; Hutchins V; Linnehan JE; Senbetta M
J Manag Care Pharm; 2013; 19(9):799-808. PubMed ID: 24156649
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone and increased survival in metastatic prostate cancer.
Berruti A; Pia A; Terzolo M
N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
[No Abstract] [Full Text] [Related]
10. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate is well tolerated without concomitant use of corticosteroids.
Attard G; Reid AH; de Bono JS
J Clin Oncol; 2010 Oct; 28(29):e560-1; author reply e562. PubMed ID: 20805462
[No Abstract] [Full Text] [Related]
12. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
[TBL] [Abstract][Full Text] [Related]
13. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Sartor O; Michels RM; Massard C; de Bono JS
Oncologist; 2011; 16(11):1487-97. PubMed ID: 22048000
[TBL] [Abstract][Full Text] [Related]
15. NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Dyer M; Rinaldi F; George E; Adler AI
Lancet Oncol; 2012 Aug; 13(8):762-3. PubMed ID: 23024987
[No Abstract] [Full Text] [Related]
16. Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
Antonarakis ES; Eisenberger MA
Nat Clin Pract Oncol; 2009 Jan; 6(1):12-3. PubMed ID: 18957947
[TBL] [Abstract][Full Text] [Related]
17. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
Ouzaid I; Ravery V; Pouessel D; Culine S
Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
[TBL] [Abstract][Full Text] [Related]
18. Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
Struss WJ; Black PC
Urology; 2017 Nov; 109():1-2. PubMed ID: 28797683
[No Abstract] [Full Text] [Related]
19. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
[TBL] [Abstract][Full Text] [Related]
20. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
